Loading...
NYSE: JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General
●S&P 500 since 1973
Market Cap
$573.99B
52w High
$251.71
52w Low
$141.50
P/E
21.58
Volume
2.41M
Outstanding Shares
2.41B
Company profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue.
CEOJoaquin Duato
SectorHealthcare
IndustryDrug Manufacturers - General
Employees138,100
IPO dateJan 2, 1943
Valuation
Forward P/E—
EV/EBITDA13.34
Enterprise value$532.3B
Stock splits
Jun 13, 20012:1
Jun 12, 19962:1
Jun 10, 19922:1
May 11, 19892:1
May 19, 19813:1
May 18, 19703:1
Jun 19, 19673:1
Profitability & growth
Revenue growth9.08%
Gross margin72.78%▲5.38%vs FY2024
Operating margin27.17%▲8.97%vs FY2024
ROE32.87%▲67.06%vs FY2024
Analyst consensus
RatingBuy
Target price$228.73▼3.97%
20
Buy
16
Hold
3
Sell
⚠ Analyst ratings tend to be lagging indicators — upgrades often follow price gains rather than precede them. Use as one signal among many.
Earnings
Last 3 reported quarters plus the next estimate. Switch into compare mode to inspect one metric year-over-year.
Next report
Apr 21, 2026
View
EPS
Actual vs estimate by quarter
Q2FY25
ActualEst.
$2.77
$2.68
Q3FY25
ActualEst.
$2.80
$2.76
Q4FY25
ActualEst.
$2.46
$2.46
Q1FY26
Next Est.
—
Revenue
Actual vs estimate by quarter
Q2FY25
ActualEst.
$23.74B
$22.85B
Q3FY25
ActualEst.
$23.99B
$23.76B
Q4FY25
ActualEst.
$24.56B
$24.15B
Q1FY26
Next Est.
—